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Abstract Mutations in the leucine-rich repeat kinase 2
(LRRK2) gene represent the most common cause of familial
Parkinson’s disease (PD), whereas common variation at the
LRRK2 locus is associated with an increased risk of idio-
pathic PD. Considerable progress has been made toward
understanding the biological functions of LRRK2 and the
molecular mechanisms underlying the pathogenic effects of
disease-associated mutations. The development of neuronal
culture models and transgenic or viral-based rodent models
have proved useful for identifying a number of emerging
pathways implicated in LRRK2-dependent neuronal dam-
age, including the microtubule network, actin cytoskeleton,
autophagy, mitochondria, vesicular trafficking, and protein
quality control. However, many important questions remain
to be posed and answered. Elucidating the molecular mech-
anisms and pathways underlying LRRK2-mediated neuro-
degeneration is critical for the identification of new
molecular targets for therapeutic intervention in PD. In this
review we discuss recent advances and unanswered ques-
tions in understanding the pathophysiology of LRRK2.
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Introduction
Parkinson’s disease (PD) is the most common neurodegen-
erative movement disorder affecting 1% to 2% of the pop-
ulation above 60 years of age [1]. Motoric abnormalities
result from the profound degeneration of distinct neuronal
populations within the brain, most prominently the dopami-
nergic neurons of the substantia nigra and their striatal
projections resulting in a dramatic reduction of dopamine
content in the caudate putamen [2, 3]. Neurodegeneration is
typically accompanied by the presence of proteinaceous
intracytoplasmic inclusions termed Lewy bodies in surviv-
ing neurons that are enriched with α-synuclein protein.
Most PD cases occur in a sporadic manner although 5% to
10% of cases are inherited with mutations identified in
several genes that clearly segregate with disease in families
with PD. Although familial PD is relatively rare, under-
standing the function of mutated gene products that influ-
ence disease susceptibility provides a unique opportunity to
elucidate the molecular pathogenic mechanisms and path-
ways underlying neuronal degeneration and to develop
disease-modifying or neuroprotective therapies.
Mutations in the leucine-rich repeat kinase 2 (LRRK2,
PARK8, OMIM 607060) gene cause late-onset autosomal-
dominant PD [4, 5], and represent the most common known
cause of familial PD. Recent genome-wide association stud-
ies also suggest that common variation at the LRRK2 locus
influences the risk of developing sporadic PD [6, 7]. Among
numerous putative pathogenic variants identified to date, at
least six missense mutations in the LRRK2 gene are known
to clearly segregate with disease (ie R1441C, R1441G,
R1441H, Y1699C, G2019S, and I2020T) [8], indicating that
they represent authentic disease-causing variants. The most
frequent LRRK2 mutation, G2019S, has been identified in
up to about 40% of familial PD cases depending on
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ethnicity, and has been detected in apparent sporadic PD
cases. The latter observation can most likely be attributed to
the incomplete penetrance of the G2019S variant, which
ranges from 28% at 59 years to 74% at 79 years [9].
The clinical features of LRRK2 mutation carriers are virtu-
ally indistinguishable from sporadic PD [9]. Neuropathological
data indicate that the majority of LRRK2 mutation carriers
display typical brainstem Lewy body pathology although there
are reported cases that exhibit either tau-positive neurofibrillary
tangle pathology, ubiquitin-positive inclusions, or the distinct
absence of inclusion pathology [5, 10–12]. This heterogeneous
pathology of LRRK2 PD brains might suggest that
LRRK2 can participate in the regulation of protein
aggregation pathways that are common to a number of
neurodegenerative diseases. The lack of protein inclu-
sion pathology in certain LRRK2 PD brains, although
rare, might also indicate that neuronal degeneration can
occur independently from inclusion formation. The sig-
nificance of LRRK2-related heterogeneous neuropathology
remains to be clarified.
In this review, we discuss recent advances in understand-
ing the physiological function of LRRK2 and the potential
mechanisms through which disease-associated mutations
precipitate selective neuronal dysfunction and degeneration
in PD.
Structure and Cellular Localization of LRRK2
LRRK2 is a multi-domain protein of 2527 amino acids that
belongs to the ROCO family of proteins. ROCO proteins
contain a characteristic Ras-of-Complex (ROC) GTPase
domain adjacent to a C-terminal-of-ROC (COR) linker re-
gion. LRRK2 also contains several distinctive domains in-
cluding a serine/threonine protein kinase domain and
putative protein-protein interaction domains flanking the
central ROC-COR-kinase catalytic region: LRRK2-
specific, ankyrin, and leucine-rich repeat motifs in the N-
terminal region and WD40 repeats near the C-terminus of
the protein (Fig. 1) [13]. The existence of multiple protein-
Fig. 1 LRRK2 is a dimeric multi-domain protein consisting of
protein-protein interaction domains surrounding a catalytic core
(ROC-COR-kinase) where the most common pathogenic mutations
are located (as indicated). Pathogenic mutations in LRRK2 lead to
decreased GTPase activity (ie, R1441C/G/H or Y1699C) or increased
kinase activity (ie, G2019S). The development of cellular and animal
models has shed light on LRRK2-related molecular pathways. LRRK2
has been implicated in regulating the microtubule network, actin cyto-
skeleton, neurite outgrowth, autophagy-lysosomal pathway, apoptosis,
mitochondrial morphology and activity, vesicular trafficking (ie, syn-
aptic vesicle exocytosis/endocytosis), dopaminergic (DA) neurotrans-
mission, protein translation, and degradation pathways, which could
potentially underlie neuronal damage. The potential functional interac-
tion of LRRK2 with α-synuclein and tau as well as the molecular
mechanisms through which disease-associated mutations lead to neuro-
degeneration require further elucidation. ERM—ezrin/radixin/moesin
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protein interaction domains could imply that LRRK2 may
act as a scaffold for the assembly of protein complexes,
some of which could regulate or be modified by the enzy-
matic domains of LRRK2 following their recruitment.
While LRRK2 interacts with a myriad of proteins, the
identification of a common LRRK2 protein complex has
not been forthcoming and is likely influenced by the cellular
milieu and/or subcompartment. Similar to other protein
kinases, LRRK2 normally exists as a dimeric structure min-
imally mediated via its ROC domain and dimerization is
required for its kinase activity and localization to cellular
membranes [14–17]. The WD40 domain also appears to be
important for dimerization and kinase activity [18].
LRRK2 is widely expressed in many tissues and cell
types [19]. LRRK2 expression is first detected in the rodent
brain by embryonic day 16 to 17 with increasing expression
during neuronal maturation and postnatal stages, whereas in
adult rodents LRRK2 mRNA is expressed at highest levels
in kidney, lung, and lymph nodes [20–25]. Notably, deletion
of LRRK2 in mice induces cytopathological abnormalities
in kidney and lung tissues [26–28]. In the mammalian brain,
LRRK2 mRNA and protein is detected at low levels in
dopaminergic neurons of the substantia nigra and ventral
tegmental area while it is abundant in dopamine-innervated
areas such as the striatum and cerebral cortex as well as in
the cerebellum and hippocampus [8, 21–23, 29]. LRRK2
protein is localized predominantly to neuronal cells under
normal conditions where it is present throughout the cyto-
plasm associated with various intracellular membranes and
vesicular structures as revealed by confocal and electron
microscopy, and subcellular fractionation [20]. In particular,
LRRK2 localizes to endosomes, lysosomes, multivesicular
bodies, mitochondrial outer membrane, lipid rafts,
microtubule-associated vesicles, the Golgi complex, and
the endoplasmic reticulum [20, 30–32]. LRRK2 is also
enriched in synaptosomal fractions from rodent brain [20].
The subcellullar localization of LRRK2 provides clues for
its physiological function(s) within neurons, for example,
participation in cytoskeletal organization and vesicular
transport, as will be discussed below. The association of
LRRK2 with intracellular membranes represents a potential
mechanism for the regulation of its dimerization and enzy-
matic activity [14], reinforcing a role for LRRK2 in mem-
brane dynamics and transport.
LRRK2 Enzymatic Activity: A Functional GTPase
and Kinase?
The kinase domain of LRRK2 shares closest sequence ho-
mology to receptor-interacting protein kinases (RIPKs) and to
mixed-lineage kinases (MLKs), a subclass of the mitogen-
activated protein kinase kinase kinase (MAPKKK) family.
LRRK2 does not appear to directly participate in MAPK
signaling in mammalian cells but can phosphorylate the
stress-activated MAP kinase kinase proteins, MKK3, 4, 6,
and 7, in vitro [33–36]. Most studies of LRRK2 kinase activ-
ity rely on in vitro autophosphorylation assays although it is
not yet clear whether autophosphorylation directly correlates
with the intrinsic activity of LRRK2 [36–38]. In vitro, LRRK2
can phosphorylate the generic kinase substrate, myelin basic
protein [37, 38], as well as two pseudosubstrate peptides,
LRRKtide and Nictide, based upon phosphorylation of
Thr558 of moesin [37, 39]. However, despite substantial in
vitro evidence demonstrating the kinase activity of LRRK2,
there is currently lack of evidence for LRRK2-mediated phos-
phorylation occurring in mammalian cells or tissues. A num-
ber of putative substrates for LRRK2 have been identified
mostly in vitro, including ezrin/radixin/moesin (ERM)
(Thr558) [37], β-tubulin (Thr107) [40], FoxO1 (Ser319)
[41], 4E-BP1 (Thr37/46) [42], MKK proteins [33], α-
synuclein (Ser129) [43], and Drosophila Futsch [44], but
these observations have not yet been independently verified
especially in mammalian cells or tissues [39, 45]. Efforts to
identify robust LRRK2 substrates in mammalian cells and
tissues by SILAC (stable isotope labeling by amino acids in
cell culture) or other phosphoproteome profiling methods are
presently being conducted in many laboratories, including our
own, and may offer further insight into the significance of
LRRK2 kinase activity. At this juncture, the most robust
substrate for LRRK2 appears to be itself where it autophos-
phorylates numerous sites in or around the GTPase domain,
some of which have been shown to regulate enzymatic activ-
ity [46–49]. It remains to be clarified whether kinase activity
simply serves to autoregulate LRRK2 activity and/or whether
bona fide substrates exist for LRRK2, in particular mammali-
an tissues, cells, and subcellular compartments.
The GTPase domain of LRRK2 shares homology to
members of the Rab GTPase family. LRRK2 can bind
GTP via its guanine nucleotide phosphate-binding (P-loop)
motif and can hydrolyze bound GTP in vitro albeit with low
activity [36, 50–53]. The presence of two enzymatic
domains suggests the potential for an intrinsic regulatory
mechanism of LRRK2 activity with parallels to the classic
Ras/Raf signal cascade. Initial studies demonstrated that
GTP binding enhanced the kinase activity of LRRK2,
whereas abolishing GTP binding via P-loop null mutations
(ie, T1348N) critically impaired kinase activity [36, 52, 53].
ROC domain mutations that enhance GTP hydrolysis also
impair kinase activity [52]. A recent study has revealed that
LRRK2 kinase activity is most likely independent of GTP
binding per se but instead depends on the capacity for GTP
binding, which may indicate the requirement for an up-
stream guanine nucleotide-binding protein for the GTP-
dependent activation of LRRK2 [54]. While GTPase activ-
ity does not appear to critically require a functional kinase
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domain [36, 52, 53], autophosphorylation within the
GTPase domain may serve a regulatory function [47–49],
which implies a complex yet poorly understood bidirection-
al relationship between the GTPase and kinase domains of
LRRK2. This concept of intramolecular regulation of
LRRK2 activity may provide an explanation for how spa-
tially distinct mutations that influence either GTPase or
kinase activity can commonly precipitate neurodegeneration
in PD. The activity of small GTPases is typically regulated
by guanine nucleotide exchange factors (GEFs), which pro-
mote the exchange of GDP for GTP leading to activation,
and GTPase-activating proteins (GAPs), which promote the
hydrolysis of bound GTP leading to inactivation.
Accordingly, a putative GEF, ARHGEF7 [55], and GAP,
ArfGAP1 [56], for LRRK2 have recently been identified.
ArfGAP1 interacts with LRRK2 in vitro and in vivo and
promotes its GTP hydrolysis activity but also serves as a
robust substrate of LRRK2-mediated phosphorylation in
vitro [56]. The absence of these regulatory factors from
previous studies may explain why LRRK2 appears to ex-
hibit poor GTPase activity in vitro.
Disease-Associated LRRK2 Mutations: Common Versus
Distinct Pathogenic Effects
The majority of familial disease-associated mutations tend
to cluster within the central ROC-COR-kinase region of
LRRK2 [8, 57]. The dominant inheritance pattern of mis-
sense mutations and the general absence of deletion or
truncation mutations reported to date provide some support
for a toxic gain-of-function mechanism rather than a loss-of-
function mechanism (ie, dominant-negative or haploinsuffi-
cient effects) underlying the pathogenic effects of mutations.
Clarifying the mechanism of action of familial mutations
and in particular their common pathogenic properties has
important implications for the development of appropriate
therapeutic strategies. For LRRK2 mutations, there is as yet
no consensus on a common pathologic effect. In almost all
functional assays reported, familial mutations do not obvi-
ously manifest a loss-of-function phenotype and are equally
if not more active than wild-type LRRK2.
The G2019S and I2020T mutations are located within the
activation loop of the kinase domain, a highly conserved
region that is critical for substrate access, where only the
G2019S variant robustly enhances kinase activity in vitro
[38, 57, 58]. While these observations may implicate en-
hanced kinase activity in the pathogenic actions of familial
mutations, it is worth remembering that other mutations
located within the ROC-COR-kinase region do not consis-
tently alter kinase activity across multiple independent stud-
ies [59]. This might suggest that kinase activity is not likely
to be the major pathogenic output of LRRK2, unless one
assumes that distinct mutations promote neuronal damage
through distinct rather than common mechanisms.
Mutations located within or near the GTPase domain (ie,
R1441C, R1441G, and Y1699C) tend to modestly impair
GTP hydrolysis activity, which could lead to a prolonged
activation of LRRK2 or a persistent interaction with an
unknown GTP-dependent interacting partner [50, 51, 60,
61]. The G2019S and I2020T mutations do not alter GTP
hydrolysis activity but could conceivably alter LRRK2 auto-
phosphorylation at sites within the GTPase domain and thus
activity [60]. At present, common alterations in enzymatic
activity are not sufficient to explain the pathogenic effects of
LRRK2 mutations.
Most evidence for the pathogenic actions of LRRK2 muta-
tions exists for the common G2019S variant. Overexpression
of the G2019S mutant (as well as wild-type and R1441C) in
cultured primary neurons or neuroblastoma cell lines induces
variable amounts of apoptotic cell death and genetic or phar-
macological inhibition of kinase activity attenuates cell death
[36, 53, 62–64•, 65]. This may suggest that LRRK2-mediated
phosphorylation of its substrates and/or itself are implicated in
pathways leading to neuronal damage. The nature of this
pathway remains elusive. It has not yet been possible to clarify
why inhibition of the kinase activity of the R1441C mutant,
which does not consistently exhibit enhanced kinase activity,
prevents LRRK2-induced neuronal cell death [53, 63, 65].
Genetic inhibition of GTPase activity by preventing GTP
binding also blocks neuronal damage induced by wild-type
and G2019S LRRK2 [36, 53]. Kinase and GTPase activity
may therefore represent useful molecular targets for interfer-
ing with LRRK2-mediated neuronal damage although the
mechanism of action is not clearly understood and these
effects have not been subjected to rigorous validation in vivo
in animal models.
The pathogenic effects of the G2019S mutation have also
been demonstrated to some extent in animal models. In
Drosophila, the transgenic expression of human G2019S
LRRK2 induces the adult-onset selective loss of dopaminer-
gic neurons and locomotor dysfunction [66], which could be
attenuated by inhibition of LRRK2 kinase activity [67], or
by overexpression of parkin [68], a gene product associated
with autosomal-recessive PD. Similarly, the delivery of
human adenoviral vectors expressing G2019S LRRK2 to
the striatum of adult rats leads to retrograde dopaminergic
axonal transport of LRRK2 and the progressive loss of
nigral dopaminergic neurons [69•]. Intriguingly, dystrophic
dopaminergic neurites containing hyperphosphorylated tau
are also produced by wild-type and G2019S LRRK2 ex-
pression in this adenoviral model, which suggests that neu-
ronal degeneration can be dissociated from protein inclusion
pathology [69•].
A second gene transfer model based on intrastriatal de-
livery of herpes simplex virus amplicon vectors expressing
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G2019S LRRK2 to adult mice induces dopaminergic neuro-
degeneration whereas genetic and pharmacological inhibi-
tion of LRRK2 kinase activity attenuate this neuronal loss
[64•]. Kinase inhibition may offer a promising therapeutic
strategy for preventing LRRK2-dependent neurodegenera-
tion but these studies await independent confirmation using
newer highly selective inhibitors of LRRK2 kinase activity
[63, 70]. While viral-based models have proved successful
in reproducing mutation-dependent, LRRK2-mediated neu-
ronal degeneration, transgenic mice overexpressing human
G2019S LRRK2 driven by the platelet-derived growth
factor-β promoter also develop age-dependent nigral dopa-
minergic neuronal loss together with the accumulation of
autophagic vacuoles and mitochondrial abnormalities but
with the distinct absence of classical protein inclusions or
aggregates [71•]. Similarly, BAC transgenic mice overex-
pressing R1441G LRRK2 develop progressive levodopa-
responsive motor deficits, reduced striatal dopamine release,
and dopaminergic axonal pathology containing hyperphos-
phorylated tau but in the absence of frank nigral neuronal
loss [72•].
A number of LRRK2 transgenic mouse models exhibit
impaired or abnormal dopaminergic neurotransmission, in-
cluding R1441G and G2019S BAC transgenic mice and
R1441C knockin mice, revealing a potential role for
LRRK2 in the nigrostriatal dopaminergic pathway [72•,
73–75]. Impaired dopaminergic neurotransmission mani-
fests in the absence of overt nigral neuronal loss or axonal
degeneration in the striatum of LRRK2 BAC mice [72•,73],
which could suggest that altered neurotransmission may
relate to the involvement of LRRK2 in regulating synaptic
vesicle trafficking and localization or could represent an
early event prior to neuronal loss [25, 60, 76]. LRRK2
normally controls the storage and mobilization of synaptic
vesicles within the presynaptic recycling pool [25], and
LRRK2 overexpression disrupts synaptic vesicle exocytosis
and endocytosis [60, 76]. Similarly, deletion of the LRRK2
homolog, lrk-1, in Caenorhabditis elegans regulates the
axonal-dendritic polarity of synaptic vesicle protein trans-
port via sorting at the Golgi apparatus [77]. It will be
important to clarify the effects of LRRK2 mutations on
nigrostriatal dopaminergic neurotransmission in rodent
models and whether this is due to synaptic pathology or to
abnormal regulation of synaptic vesicle transport and recy-
cling within dopaminergic neurons.
Another common effect induced by LRRK2 mutations is
the induction of neuronal cell death pathways. Initially, the
R1441C, Y1699C, and G2019S mutants were shown to
promote neuronal cell death through the intrinsic
mitochondrial-dependent apoptotic cell death pathway in-
volving nuclear condensation, mitochondrial cytochrome c
release, and caspase-3 activation [62, 65, 78]. Apoptotic cell
death could be blocked by caspase-3 inhibition and by
deletion of Apaf-1, which is required for apoptosome for-
mation and caspase activation [78]. Activated caspase-3 has
also been observed in rat dopaminergic neurons transduced
via intranigral delivery of AAV2 vectors expressing the
G2019S but not wild-type LRRK2 kinase domain [79].
Since the isolated kinase domain of LRRK2 is not known
to be functional [37], cell death in this model most likely
occurs in a kinase-independent manner. LRRK2 mutations
have also been shown to enhance the interaction with the
death adaptor Fas-associated protein with death domain
(FADD), which mediates the recruitment and activation of
caspase-8 required for the extrinsic cell death pathway [80].
Mutant LRRK2-dependent neuronal death is dependent on
FADD and caspase-8 [80]. It will be important to assess
whether apoptotic markers, including caspases, are induced
in rodent models expressing full-length mutant LRRK2 that
exhibit neurodegeneration and which cell death pathways,
intrinsic and/or extrinsic, are potentially involved. Inhibition
of apoptotic pathways as a strategy for preventing LRRK2-
dependent neuronal damage warrants further validation in
animal models.
Molecular Pathways Implicated in LRRK2-Induced
Neuronal Damage
LRRK2 has so far been implicated in diverse molecular
pathways and cellular functions, such as vesicular traffick-
ing, neurite outgrowth, cytoskeletal regulation, autophagy,
mitochondrial function, and translational control (Fig. 1).
The localization of LRRK2 to intracellular vesicles and
membranous compartments in neurons and the presence of
kinase and GTPase enzymatic domains provide potential
clues to its physiological function. For example, microtu-
bule dynamics and neuronal polarization as well as axon
growth are known to be regulated by signaling pathways
controlled by kinases and small GTPases [81]. Accordingly,
LRRK2 plays a role in regulating the length and complexity
of neuronal processes.
Neurite Morphology, Actin Cytoskeleton, and Microtubules
Overexpression of G2019S or I2020T LRRK2 robustly
reduces neurite length and branching in neural cell lines
and cultured primary neurons [71•, 79, 82, 83•], whereas
the effects of other familial mutations are less prominent.
Oppositely, ablation of LRRK2 expression promotes neurite
length and complexity [79, 83•]. Kinase activity appears to
be required for LRRK2-induced neurite shortening [63, 79].
One potential mechanism for regulating neurite morphology is
through the LRRK2-mediated phosphorylation of proteins
that regulate microtubule assembly, cytoskeletal organization,
and axonal growth. The ERM protein family was originally
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identified as putative substrates of LRRK2 kinase activity in
vitro [37], and it was subsequently shown that ERM protein
phosphorylation by LRRK2 occurring in neuronal filopodia
promotes rearrangement of the actin cytoskeleton and impairs
the neurite outgrowth of developing neurons [37, 83•]. It is not
yet clear whether ERM proteins represent direct or indirect
substrates of LRRK2-mediated phosphorylation within neu-
rons [83•]. The effects of G2019S LRRK2 on neurite morphol-
ogy can be rescued by overexpression of the Rho GTPase,
Rac1 [84], which regulates actin cytoskeleton remodeling,
and by inhibition of the GTPase-activating protein, ArfGAP1
[56], which functions as a GAP for LRRK2 and is involved in
the dissociation of coat proteins from intracellular vesicles.
Autophagy also appears to be required for the effects of
G2019S LRRK2 on neurite morphology [82].
LRRK2 can also regulate the microtubule network. LRRK2
was shown to physically interact with α- and β-tubulin via its
GTPase domain and can phosphorylate brain-derivedβ-tubulin
isoforms at Thr107 and increase microtubule stability in vitro,
althoughβ-tubulin phosphorylation has not yet been confirmed
in vivo [40, 85]. Overexpression of wild-type or G2019S
LRRK2 in transgenic mice impairs microtubule assembly con-
sistent with enhanced tubulin polymerization [86••]. Intact
kinase activity and the WD40 domain of LRRK2 may be
required for the association with microtubules [87]. A recent
study suggests that G2019S LRRK2 expression may cause
dendrite degeneration in Drosophila by promoting the phos-
phorylation of the microtubule-associated protein tau at Thr212
by the GSK3β homolog Shaggy, which induces tau hyper-
phosphorylation and its mislocalization to dendrites [44]. The
abnormal accumulation, processing, or hyperphosphorylation
of tau also occurs in vivo in LRRK2 PD brains and in certain
transgenic and viral-based rodent models expressing R1441C,
R1441G, or G2019S LRRK2 [5, 69•, 72•, 73, 74, 79, 88],
which may reflect perturbed microtubule assembly. LRRK2
may therefore regulate the organization of the actin cytoskele-
ton and microtubule assembly by direct or indirect signaling to
some of its protein components, which may underlie the effects
of LRRK2 on neurite morphology. It is not yet clear whether
the effects of LRRK2 mutations on neurite outgrowth reflect
neuronal toxicity that occurs prior to neuronal cell death, or
whether they reflect a physiological function of LRRK2 in
regulating neurite morphology. That LRRK2 ablation
oppositely enhances neurite outgrowth could argue in favor
of the latter mechanism. Nevertheless, neurite phenotypes
provide a sensitive measure of LRRK2 activity and may be
useful for identifying genetic modifiers or defining the efficacy
of small molecule LRRK2 inhibitors.
Inclusion Formation and Abnormal Autophagy
PD brains harboring LRRK2 mutations exhibit heteroge-
neous protein inclusion pathology, including Lewy bodies,
neurofibrillary tangles, and ubiquitin deposits, although the
majority of cases manifest typical brainstem α-synuclein-
positive Lewy body pathology [10, 11]. The contribution of
LRRK2 to the formation of intraneuronal protein inclusions
is not yet clear. In general, LRRK2 does not appear to be a
common component of Lewy bodies or other protein inclu-
sions based on studies using validated antibodies [19, 20,
22, 65, 89], suggesting that it is not likely to be a core
structural component of such inclusions. LRRK2 could
potentially modulate pathways that regulate protein accu-
mulation and/or aggregation, such as the ubiquitin-
proteasomal system (UPS), the autophagy-lysosomal path-
way, molecular chaperones, protein translation, axonal or
microtubule transport, or vesicular trafficking. A recent
study suggests that LRRK2 may cause a general impairment
of proteasomal degradation leading to the accumulation of
proteasomal substrates including α-synuclein [90].
However, the mechanism underlying α-synuclein aggrega-
tion in LRRK2 PD brains is not known. What is also not yet
known is whether α-synuclein (or tau) aggregation is criti-
cally required for mediating LRRK2-dependent neurode-
generation or instead represents a benign effect secondary
to neuronal dysfunction. The application of viral vectors
expressing LRRK2 mutants to α-synuclein or tau knockout
mice, or crossbreeding studies of appropriate mouse models,
will be important for clarifying their contribution to dopa-
minergic neuronal degeneration.
A recent study has attempted to evaluate the pathophys-
iological interaction of LRRK2 and α-synuclein in vivo in
transgenic mice. G2019S LRRK2 expression enhances the
abnormal somatic accumulation of α-synuclein and neuro-
pathology that develop in forebrain neurons of A53T α-
synuclein transgenic mice whereas LRRK2 deletion reduces
these phenotypes [86••]. Whether LRRK2 and α-synuclein
functionally interact in nigrostriatal dopaminergic neurons
of mice is not yet known. Potential mechanisms for the
modulatory actions of LRRK2 include impaired Golgi com-
plex integrity, perturbed microtubule assembly, or UPS dys-
function that are all modulated by LRRK2 in this A53T α-
synuclein mouse model [86••]. LRRK2 deletion appears to
be protective in this A53T α-synuclein model, thereby sug-
gesting that LRRK2 inhibition could provide a potential
strategy for preventing α-synuclein-related neuronal toxici-
ty. However, as a cautionary note, LRRK2 deletion in mice
results in kidney and lung pathology that is characterized by
impaired protein degradation pathways, increased apoptotic
cell death, inflammatory responses, and abnormalities in the
autophagy-lysosomal pathway [26–28]. LRRK2 could po-
tentially modulate α-synuclein-related neuropathology in
transgenic mice by priming α-synuclein aggregation or
could act downstream to mediate α-synuclein-induced neu-
ronal toxicity. Alternatively, LRRK2 might inhibit α-
synuclein metabolism or turnover via the proteasomal and/
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or lysosomal degradation pathways or could promote α-
synuclein protein translation. It will be important to clarify
whether the effects of modulating LRRK2 expression in
animal models are specific to α-synuclein (or tau) or simply
result from a global effect on protein turnover and/or
translation.
LRRK2 mutations have been shown to promote inclusion
formation in neural cell lines and cultured neurons through a
kinase-dependent mechanism that could be correlated with
cell death [62, 65]. There is some variability in the mor-
phology and frequency of LRRK2 inclusions with different
mutations [62, 65]. The exact nature or role of these inclu-
sions is unclear. LRRK2 inclusion bodies may represent
filamentous structures resulting from LRRK2 oligomeriza-
tion that are surrounded by the cytoskeletal filament vimen-
tin, stain positive for γ-tubulin, and can be disrupted by the
microtubule polymerization inhibitor, nocodazole, suggest-
ing that they are formed by active recruitment to the micro-
tubule network or to cytoskeletal elements [65, 87]. In
primary neurons, G2019S and I2020T LRRK2 form
spheroid-like aggregates in neuronal processes that also
contain hyperphosphorylated tau, swollen lysosomes, multi-
vesicular bodies, distended vacuolated mitochondria, and
disrupted cytoskeletal components [79]. In general,
LRRK2 inclusions most likely result from structural or
functional perturbations of the microtubule network and/or
actin cytoskeleton, which may influence their assembly,
dynamic organization, and vesicular transport. It is not clear
whether these LRRK2 inclusions are required for LRRK2-
dependent neuronal degeneration. Furthermore, LRRK2
does not appear to form inclusions in idiopathic PD brains
[22, 65, 89], although a rigorous analysis of LRRK2 animal
models and LRRK2 mutant PD brains awaits the develop-
ment of improved antibodies.
LRRK2 has been shown to modulate the autophagy
pathway. Impaired neurite outgrowth induced by G2019S
LRRK2 is prevented by genetic inhibition of autophagy
components but exacerbated by rapamycin, an activator of
autophagy [82]. G2019S LRRK2 also promoted the accu-
mulation of autophagic vacuoles in neuritic and somatic
compartments of cultured neurons although it is not known
whether this results from enhanced autophagy, impaired
autophagic flux, or impaired fusion of autophagosomes with
lysosomes [82]. LRRK2 localizes to autophagic vacuoles
and multivesicular bodies in human brain and cultured hu-
man cells, while the overexpression of R1441C or G2019S
LRRK2 in human cells promotes the accumulation of multi-
vesicular bodies and large autophagic vacuoles containing
incompletely digested material and increased levels of p62
[20, 30, 79]. In PD and dementia with Lewy bodies brains,
LRRK2 abnormally accumulates in the endosomal-
lysosomal compartment of neurons [89]. Impaired autoph-
agy and endocytic vesicular trafficking are also evident in a
yeast model expressing human LRRK2 and correlate with
cellular toxicity [60]. The accumulation of autophagic
vacuoles is also observed in the brains of aged G2019S
and R1441C LRRK2 transgenic mice [71•]. The mecha-
nisms underlying the effects of LRRK2 on the autoph-
agy pathway are poorly understood. A recent study
suggests that LRRK2 kinase activity may promote
autophagy induction through activation of NAADP (nic-
otinic acid adenine dinucleotide phosphate) receptors,
which mediate calcium efflux from lysosomes [91].
Despite substantial evidence demonstrating abnormal
autophagy in LRRK2 disease models, what is not yet clear
is whether autophagy is critically required for LRRK2-
dependent neurodegeneration. Future studies that acti-
vate or inhibit autophagy pathways in LRRK2 animal
models with neurodegeneration will be important for clarify-
ing the role of autophagy and exploring the therapeutic po-
tential of this pathway.
Mitochondria
LRRK2 may regulate mitochondrial activity, morphology,
and turnover [92]. LRRK2 localizes to the outer membrane
of mitochondria in the mammalian brain [20]. The brains of
aged G2019S LRRK2 transgenic mice reveal the abnormal
accumulation of condensed and aggregated mitochondria
consistent with altered mitochondrial autophagy (mitoph-
agy) [71•]. G2019S LRRK2 expression also exacerbates
structural and functional mitochondrial abnormalities that
occur in neurons due to A53T α-synuclein expression in
transgenic mice [86••]. In cultured fibroblasts derived from
PD patients harboring the LRRK2 G2019S mutation, mito-
chondrial membrane potential and ATP levels are reduced
whereas mitochondrial elongation and interconnectivity
were increased, suggesting impaired mitochondrial function
and morphology [93]. LRRK2 has recently been shown to
regulate mitochondrial dynamics and function through a
direct interaction with Drp1, a small GTPase required for
mitochondrial fission [94]. LRRK2 mutations enhance mi-
tochondrial fragmentation, reduce ATP levels, and increase
reactive oxygen species in neurons through a Drp1-
dependent mechanism that may involve the recruitment of
Drp1 to mitochondria via its interaction with LRRK2 [94].
Importantly, neuronal cell death induced by mutant LRRK2
could be prevented by inhibition of Drp1 or by promoting
mitochondrial fusion via overexpression of mitofusin 2 [94],
suggesting that inappropriate mitochondrial fission may un-
derlie the neurotoxic effects of LRRK2. Therefore, impaired
mitochondrial function and morphology may contribute
to LRRK2-dependent neurodegeneration and it will be
important to evaluate this pathway in LRRK2 animal
models potentially by modulating mitochondrial fission
and fusion.
Curr Neurol Neurosci Rep (2012) 12:251–260 257
Conclusions and Future Outlook
Studies in cultured primary neurons and animal models have
substantially advanced our understanding of the pathophys-
iology of LRRK2. Disease-associated mutations alter enzy-
matic activity in vitro but also induce phenotypes in cultured
neurons in a kinase-dependent and occasionally a GTPase-
dependent manner. It will be important to clarify whether
kinase inhibition represents a feasible strategy for attenuat-
ing LRRK2-dependent dopaminergic neurodegeneration, or
related behavioral and pathological phenotypes, in currently
available viral-based and transgenic animal models. A
deeper understanding of the role of kinase activity in regu-
lating LRRK2 activity, substrate phosphorylation, and asso-
ciated downstream signaling pathways is of critical
importance. Additional studies are still required to validate
GTPase activity as a viable molecular target for inhibiting
LRRK2 activity. At the molecular level, a number of in-
triguing pathways mostly familiar to PD research are emerg-
ing as potential candidates for an involvement in LRRK2-
related neuronal damage, including the microtubule net-
work, actin cytoskeleton, vesicular trafficking, autophagy,
mitochondria, protein degradation pathways, and transla-
tional control. The major challenge will be to determine
which if any of these pathways are most important for
mediating the pathogenic effects of LRRK2 mutations in
neurons and validation of such mechanisms in appropriate
LRRK2 animal models. A complete understanding of
LRRK2 function and the pathogenic mechanisms of familial
mutations will offer a number of opportunities for the iden-
tification of novel molecular targets that might prove useful
for attenuating LRRK2-dependent neurodegeneration in
PD.
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